4123.TWOCenter Lab.
晟德 · Biotech and medical · Taipei Exchange · Taiwan
The answers
Four readings from the exchange's own figures. Each line says what it is based on.
- Is it growing?Good
- Revenue +22% this year to August 2026, against the same months last year.
- Is it a good business?To watch
- It earns −99% a year on its shareholders' equity (H1 2026, annualised).
- Is it safe?Good
- Equity is 72% of its assets; the rest is owed to others.
- Is the price fair?Fair
- 23.3 times earnings, against 19.6 for the median listed stock in Taiwan.
Size and price
As of Sep 24, 2026.
market cap · NT$25.0B
P/E · market median 19.6
dividend yield
The price chart appears once Ryufin has collected a month of closes (collecting since Sep 24, 2026).
Revenue, month by month
Taiwanese companies report revenue every month, by the 10th of the next.
revenue in August 2026
on the same month last year
this year so far, on last year
The latest report
H1 2026, year to date, consolidated.
- Revenue
- NT$898M
- Operating income52% of revenue
- NT$467M
- Net incometo shareholders
- −NT$8.5B
- Earnings per share
- −NT$11.24
- Total assets
- NT$24.0B
- Equity
- NT$17.2B
- Book value per share
- NT$22.77
Also in biotech and medical
The largest listed peers in Taiwan, by market cap.
- 6446.TW PharmaEssentia
- $15.4B
- 6919.TW Caliway
- $3.9B
- 7799.TW HNMC
- $2.5B
- 6949.TW Pell BMT
- $2.1B
- 6472.TW Bora
- $1.7B
- 1795.TW Lotus Pharm
- $1.5B
Source: Taiwan Stock Exchange and Taipei Exchange OpenAPI, published on data.gov.tw under the Open Government Data License, version 1.0. Ryufin computed the answers, market cap and growth rates from that data. US dollar figures use the BIS TWD/USD rate. Prices are end of day. Price history on Ryufin starts on Sep 24, 2026 and grows by one close each trading day.